EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

RSV F evolution escapes some monoclonal antibodies but does not strongly erode neutralization by human polyclonal sera

Cassandra A L Simonich iD, Teagan E McMahon iD, Xiaohui Ju iD, Timothy C Yu, Natalie Brunette, Terry Stevens-Ayers iD, Michael J Boeckh iD, Neil P King, Alexander L Greninger iD, Jesse D Bloom iD

Journal of Virology · 22.07.2025 · 99 (7)

DOI: 10.1128/jvi.00531-25 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Virology, erschienen am 22.07.2025. Verfasst von Cassandra A L Simonich und 9 weiteren Autor:innen. Beteiligte Einrichtung: Basic Sciences and Computational Biology Divisions, Fred Hutchinson Cancer Center, Seattle, Washington, USA. Hauptthemen laut MEDLINE: Antibodies, Neutralizing, Antibodies, Monoclonal, Respiratory Syncytial Virus, Human, Viral Fusion Proteins. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 108 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS, National Science Foundation, Bill and Melinda Gates Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Vaccines and monoclonal antibodies targeting the respiratory syncytial virus (RSV) fusion protein (F) have recently begun to be widely used to protect infants and high-risk adults. Some other viral proteins evolve to erode polyclonal antibody neutralization and escape individual monoclonal antibodies. However, the impact of RSV F evolution on antibody neutralization is not yet thoroughly understood. Here, we develop an experimental system for measuring neutralization titers against RSV F using pseudotyped lentiviral particles. This system is easily adaptable to evaluate neutralization of relevant clinical strains. We apply this system to demonstrate that the natural evolution of RSV F leads to escape from some monoclonal antibodies, but at most modestly affects neutralization by polyclonal serum antibodies. Overall, our work sheds light on RSV antigenic evolution and describes a tool to measure the ability of antibodies and sera to neutralize contemporary RSV strains. IMPORTANCE We describe an efficient approach to measure how antibodies inhibit infection by historical and recent human strains of respiratory syncytial virus (RSV). This approach is useful for understanding how viral evolution affects antibody immunity. We apply this approach to demonstrate that RSV evolution can escape some monoclonal antibodies, but polyclonal serum antibodies are less impacted by viral evolution. This information is relevant given the recent development of RSV preventative measures, including monoclonal antibodies and vaccines.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, NeutralizingAntibodies, MonoclonalRespiratory Syncytial Virus, HumanViral Fusion ProteinsAntibodies, ViralRespiratory Syncytial Virus InfectionsHumansNeutralization TestsEvolution, MolecularAnimals

Stichwörter der Autor:innen

RSVRSV evolutionlentiviral pseudotypingmonoclonal antibodiesrespiratory syncytial virusviral evolution

Substanzen

Antibodies, NeutralizingAntibodies, MonoclonalViral Fusion ProteinsAntibodies, ViralF protein, human respiratory syncytial virus

Autor:innen und Institutionen

  • Basic Sciences and Computational Biology Divisions, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
  • Department of Pediatrics, University of Washington, Seattle, Washington, USA.
  • Pediatric Infectious Diseases Division, Seattle Children's Hospital, Seattle, Washington, USA.
  • Molecular and Cellular Biology Graduate Program, University of Washington and Fred Hutch Cancer Center, Seattle, Washington, USA.
  • Department of Biochemistry, University of Washington, Seattle, Washington, USA.
  • Institute for Protein Design, University of Washington, Seattle, Washington, USA.

ORCID-Profile: Cassandra A L Simonich, Teagan E McMahon, Xiaohui Ju, Terry Stevens-Ayers, Michael J Boeckh, Alexander L Greninger, Jesse D Bloom

Förderung

  • NIH HHS
  • National Science Foundation
  • Bill and Melinda Gates Foundation
  • NIAID NIH HHS
  • NICHD NIH HHS
  • Howard Hughes Medical Institute
  • NCI NIH HHS
  • National Institutes of Health

Zitieren

APA

Simonich, C. A. L., McMahon, T. E., Ju, X., Yu, T. C., Brunette, N., Stevens-Ayers, T., Boeckh, M. J., King, N. P., Greninger, A. L., & Bloom, J. D. (2025). RSV F evolution escapes some monoclonal antibodies but does not strongly erode neutralization by human polyclonal sera. Journal of Virology, 99(7). https://doi.org/10.1128/jvi.00531-25

Vancouver

Simonich CAL, McMahon TE, Ju X, Yu TC, Brunette N, Stevens-Ayers T, et al. RSV F evolution escapes some monoclonal antibodies but does not strongly erode neutralization by human polyclonal sera. Journal of Virology. 2025;99(7). doi:10.1128/jvi.00531-25

BibTeX
@article{Simonich2025,
  author = {Simonich, Cassandra A L and McMahon, Teagan E and Ju, Xiaohui and Yu, Timothy C and Brunette, Natalie and Stevens-Ayers, Terry and Boeckh, Michael J and King, Neil P and Greninger, Alexander L and Bloom, Jesse D},
  title = {RSV F evolution escapes some monoclonal antibodies but does not strongly erode neutralization by human polyclonal sera},
  journal = {Journal of Virology},
  year = {2025},
  volume = {99},
  number = {7},
  doi = {10.1128/jvi.00531-25}
}
Kostenlos starten →